Biobanks for biomarkers in neurological disorders. The Da Vinci bridge for optimal clinico-pathological connection

Journal of the Neurological Sciences

Volumn 283, Issue 1-2, 2009, Pages 119-126

  Ravid, Rivka ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Biomarkers; Blood; BTB banks; Cells; CSF; Dementia; Early diagnostics

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; ISOPROSTANE; PHOSPHOPROTEIN; TAU PROTEIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ARTICLE; BIOBANK; BLOOD; BRAIN; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONSTRUCTION WORK; DA VINCI BRIDGE; DATA BASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; HEALTH CARE FACILITY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URINE;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; BRAIN DISEASES; CYTOKINES; DEMENTIA; HUMANS; MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 67650155260     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.02.364     Document Type: Article

References (85)

1. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
2. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand 107 (2003) 47-51
3. Blennow K., Zetterberg H., Minthon L., Lannfelt L., Strid S., Annas P., Basun H., and Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 23:419 1 (2007) 18-22
4. Blennow K., Vanmechelen E., and Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24 (2001) 87-97
5. Blennow K., Zetterberg H., Minthon L., Lannfelt L., Strid S., Annas P., Basun H., and Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419 (2007) 18-22
6. Liao P.C., Lin C., and Kuo Y.M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics-Clin Appl 1 (2007) 506-512
7. Nedelkov D., Kiernan U.A., Niederkofler E.E., Tubbs K.A., and Nelson R.W. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 102 (2005) 10852-10857
8. Ertekin-Taner N., Younkin L.H., Yager D.M., Parfitt F., Baker M.C., Asthana S., Hutton M.L., Younkin S.G., and Graff-Radford N.R. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70 (2008) 596-606
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
10. Roses A.D., and Saunders A.M. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer's disease. Int Psychogeriatr 9 Suppl 1 (1997) 277-288 discussion 317-21
11. Roses A.D. On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. J Alzheimers Dis 9 (2006) 361-366
12. Guerreiro R.J., Santana I., Bras J.M., Santiago B., Paiva A., and Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener Dis 4 (2007) 406-412
13. Korczyn A.D. Mixed dementia-the most common cause of dementia. Ann N Y Acad Sci 977 (2002) 129-134
14. Levy S., McConville M., Lazaro G.A., and Averback P. Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease. J Clin Lab Anal 21 (2007) 24-33
15. Goodman I., Golden G., Flitman S., Xie K., McConville M., Levy S., Zimmerman E., Lebedeva Z., Richter R., Minagar A., and Averback P. A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease. J Am Med Dir Assoc. 8 6 (2007) 21-30
16. Goodman I.J. Practical utility of urinary assay in the diagnosis of Alzheimer's disease: Alzheim Alert. Expert Rev Mol Diagn 8 (2008) 21-28
17. Galasko D., Chang L., and Motter R. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
18. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., and Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A β-40, and A β1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44 (1998) 17-26
19. Galimberti D., Schoonenboom N., Scarpini E., and Scheltens P. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 53 (2003) 547-548
20. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
21. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., and Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54 (2000) 1960-1964
22. Vanmechelen E., Vanderstichele H., and Davidsson P. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285 (2000) 49-52
23. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297 (2001) 187-190
24. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., and Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?. J Neurol Neurosurg Psychiatry 71 (2001) 401-403
25. Otto M., Wiltfang J., Cepek L., et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58 (2002) 192-197
26. Le-Niculescu H., Kurian S.M., Yehyawi N., Dike C., Patel S.D., Edenberg H.J., Tsuang M.T., Salomon D.R., Nurnberger J.I.J., and Niculescu A.B. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry (Feb 26 2008)
27. Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., Van Swieten J.C., and Scheltens P. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62 (2004) 1580-1584
28. Pijnenburg Y.A., Mulder J.L., van Swieten J.C., Uitdehaag B.M., Stevens M., Scheltens P., and Jonker C. Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. Dement Geriatr Cogn Disord 25 (2008) 157-164
29. Pijnenburg Y.A., Janssen J.C., Schoonenboom N.S., Petzold A., Mulder C., Stigbrand T., Norgren N., Heijst H., Hack C.E., Scheltens P., and Teunissen C.E. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord 23 (2007) 225-230
30. Pijnenburg Y.A., Schoonenboom N.S., Rosso S.M., Mulder C., Van Kamp G.J., Van Swieten J.C., and Scheltens P. CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 62 (2004) 1649
31. Avila J., Lucas J.L., Perez M., and Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 84 (2004) 361-384
32. Lewczuk P., Esselmann H., Bibl M., Beck G., Maler J.M., Otto M., Kornhuber J., and Wiltfang J. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 23 (2004) 115-122
33. Hampel H., and Teipel S.J. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 17 (2004) 350-354
34. Maruyama M., Matsui T., Tanji H., Nemoto M., Nemoto M., Tomita N., Ootsuki M., Arai H., and Sasaki H. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 61 (2004) 716-720
35. Stefani A., Martorana A., Bernardini S., Mercati F., Orlacchio A., and Pierantozzi M. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci 251 (2006) 124-128
36. Reiman E.M. Linking brain imaging and genomics in the study of Alzheimer's disease and aging. Ann N Y Acad Sci 1097 (2007) 94-113
37. Bian H., Van Swieten J.C., Leight S., Massimo L., Wood E., Forman M., Moore P., de Koning I., Clark C.M., Rosso S., Trojanowski J., Lee V.M., and Grossman M. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70 (2008) 1827-1835
38. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., and Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 (2007) 1359-1362
39. Migliore L., Fontana I., Colognato R., Coppede F., Siciliano G., and Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26 (2005) 587-595
40. Kadioglu E., Sardas S., Aslan S., Isik E., and Esat Karakaya A. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 9 (2004) 203-209
41. de Leon M.J., Mosconi L., Blennow K., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Tsui W., Saint Louis L.A., Sobanska L., Brys M., Li Y., Rich K., Rinne J., and Rusinek H. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 1097 (2007) 114-145
42. de Leon M.J., Mosconi L., Li J., De Santi S., Yao Y., Tsui W.H., Pirraglia E., Rich K., Javier E., Brys M., Glodzik L., Switalski R., Saint Louis L.A., and Pratico D. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 254 (2007) 1666-1675
43. Brys M., Pirraglia E., Rich K., Rolstad S., Mosconi L., Switalski R., Glodzik-Sobanska L., De Santi S., Zinkowski R., Mehta P., Pratico D., Saint Louis L.A., Wallin A., Blennow K., and de Leon M.J. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007)
44. Maddalena A., Papassotiropoulos A., Muller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., and Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide(42). Arch Neurol 60 (2003) 1202-1206
45. Grinberg LT, Amaro E, Teipel S, dos Santos DD, Pasqualucci CA, Leite RE, Camargo CR, Gonçalves JA, Sanches AG, Santana M, Ferretti RE, Jacob-Filho W, Nitrini R, Heinsen H; Brazilian Aging Brain Study Group. Assessment of factors that confound MRI and neuropathological diagnosis of human postmortem brain tissue. Cell Tissue Bank. 2008 Sep;9(3):195-203.
46. Grinberg L.T.A.-J. E., Santos D.D., Pachaco S.P., Ferretti R.E.L., Leite R.E.P., Pasqualucci C.A., Teipel S.J., Flatz W.H., and Heinsen H. Brazilian Aging Brain Study Group. Improved Detection of Incipient Vascular Changes By a Biotechnological Platform Combining post mortem MRI in situ With Neuropathology. J Neurol Sci 283 (2009) 2-8 (this issue)
47. Antonini A., and DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med 5 (2004) 201-206
48. Antonini A. The role of 123I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. Neuropsychiatr Dis Treat 3 (2007)
49. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., Van Kamp G.J., Barkhof F., and Scheltens P. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 29 (2008) 669-675
50. Korczyn A.D., and Reichmann H. Dementia with Lewy bodies. J Neurol Sci 248 (2006) 3-8
51. Ewers M., Buerger K., Teipel S.J., Scheltens P., Schröder J., Zinkowski R.P., Bouwman F.H., Schönknecht P., Schoonenboom N.S., Andreasen N., Wallin A., DeBernardis J.F., Kerkman D.J., Heindl B., Blennow K., and Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69 (2007) 2205-2212
52. Bouwman F.H., van der Flier W.M., Schoonenboom N.S., van Elk E.J., Kok A., Rijmen F., Blankenstein M.A., and Scheltens P. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69 (2007) 1006-1011
53. Bouwman F.H., Schoonenboom S.N., van der Flier W.M., van Elk E.J., Kok A., Barkhof F., Blankenstein M.A., and Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 28 (2007) 1070-1074
54. Savaskan E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2 (2005) 29-35
55. Hamouda H.O., Chen P., Levoye A., et al. Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. J Pineal Res 43 (2007) 10-15
56. Biroccio A., Del Boccio P., Panella M., Sato T., et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 6 (2006) 2305-2313
57. Castano E.M., Roher A.E., Esh C.L., Kokjohn T.A., and Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28 (2006) 155-163
58. Uberti D., Lanni C., Racchi M., Govoni S., and Memo M. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener Dis 5 (2008) 209-211
59. Goldstein D.S., Holmes C., Bentho O., Sato T., Moak J., Sharabi Y., Imrich R., Conant S., and Eldadah B.A. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14 8 (2008 Dec) 600-607
60. Cosentino S., Scarmeas N., Helzner E., et al. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70 (2008) 1842-1849
61. Olichney J.M., Taylor J.R., Gatherwright J., et al. Patients with MCI and N400 or P600 abnormalities are at very high risk for conversion to dementia. Neurology 70 (2008) 1763-1770
62. van der Flier W.M., Staekenborg S., Pijnenburg Y.A., et al. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord 23 (2007) 42-46
63. Scherzer C.R., Eklund A.C., Morse L.J., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104 (2007) 955-960
64. Maes O.C., Kravitz S., Mawal Y., et al. Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol Dis 24 (2006) 89-100
65. Webster J.A., Myers A.J., Pearson J.V., et al. Sorl1 as an Alzheimer's disease predisposition gene?. Neurodegener Dis 5 (2008) 60-64
66. Reiman E.M., Webster J.A., Myers A.J., et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54 (2007) 713-720
67. www.leonardobridgeproject.org.
68. Wiltfang J., Lewczuk P., Riederer P., et al. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 6 (2005) 69-84
69. Ravid R., and Swaab D.F. Brain banking in Alzheimer's disease: pitfalls and potentials. Neuropathol Appl Neurobiol 21 (1995) 18-19
70. Ravid R., and Swaab D.F. The Netherlands brain bank-a clinico-pathological link in aging and dementia research. J Neural Transm 39 (1993) 143-153 Suppl.
71. Ravid R., van Zwieten E.J., and Swaab D.F. Brain banking and the human hypothalamus: factors to match for, pitfalls and potentials. Human Hypothalamusin Health and Disease (1992) 83-95
72. Ravid R., Swaab D.F., van Zwieten E.J., and Salehi A. Controls are what make a brain bank go round (1995), IOS Press, Amsterdam
73. Ravid R. Standard operating procedures, ethical and legal regulations in BTB (Brain/Tissue/Bio) banking: what is still missing?. Cell Tissue Bank 9 (2008) 121-137
74. Crystal H.A., and Davies P. Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go. Neurology 70 (2008) 586-587
75. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
76. Kapaki E. Highly increased CSF tau protein and decreased b-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?. Neurol Neurosurg Psychiatry 71 (2001) 401-403
77. Nielsen A.S., Ravid R., Kamphorst W., and Jorgensen O.S. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimers Dis 5 (2003) 119-125
78. see www.prize4life.org.
79. Van Rooij F.G., Schelhaas H., Lammers G.J., Verbeek M.M., and Overeem S. CSF hypocretin-1 levels are normal in patinets with amyotrphic lateral sclerosis. Amyotrop Lateral Scler (2008) On line Aug 7:1-3
80. Ginsburg G.S., Burke T.W., and Febbo P. Centralized biorepositories for genetic and genomic research. JAMA 299 11 (Mar 19 2008) 1359-1361
81. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P. Cerebrospinal fluids biomarkers in Parkinson's Disease with dementia and dementia with Lewy Bodies. Biological Psychiatry.
82. Liang W.S., Reiman E.M., Valla J., et al. Alzheimer's disease is associated with reduced expression of energy metabolism in posterior cingulated neurons. Proc Natl Acad Sci U S A 105 11 (2008) 4441-4446
83. Fagan A.M., Roe C.M., Xiong C., et al. Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64 3 (2007) 343-349
84. P. Balley. Biological markers in Alzheimer's disease. Can J. Neurol Sci. 34: 72-76.
85. ISBER Best practices for repositories. Cell preservation Technology (2008). http://www.isber.org www.isber.org